Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001537

Drug Information
NameXimelegatran
CompanyAstraZeneca
IndicationAtrial fibrillation, venous thromboembolism, myocardial infarction
[ICD9: 410, 427.31, 453   ICD10: I21, I22, I48, I80-I82]
Marketed    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/
h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1
InChIKeyIYOZTVGMEWJPKR-VOMCLLRMSA-N
Canonical SMILESCC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N    
Isomeric SMILESC[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
CAS NumberCAS 192939-46-1
PubChem Compound IDCID 448042.
SuperDrug ATC IDB01AE05
SuperDrug CAS ID192939461;
TargetThrombinInhibitor[1]
Ref 1Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543